Hikma Loan 2025
Sector: Hospital • Location: Jordan
Source: International Finance Corporation (IFC)
Hikma Pharmaceuticals PLC (“Hikma” or the “Company” or together with its subsidiaries “the Group”) is a pharmaceutical company incorporated in the United Kingdom (UK) and listed on the London Stock Exchange. While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (MENA) region, North America and Europe with
Project Information FAQ
Project Information
Want to explore the full details? View the full report
Participants
Sponsoring Agency | Obfuscated Data |
Company | Obfuscated Data |
Status
Original status | active |
Taiyo status | Obfuscated Data |
Taiyo last update | 00-00-0000 |
Available timestamps | 00-00-0000 |
Available timestamp type | Obfuscated Data |
Contact
Contact name | Obfuscated Data |
Phone | 0000000000 |
ObfuscatedData@email.com | |
Address | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Description
Description | Hikma Pharmaceuticals PLC (“Hikma” or the “Company” or together with its subsidiaries “the Group”) is a pharmaceutical company incorporated in the United Kingdom (UK) and listed on the London Stock Exchange. While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (MENA) region, North America and Europe with 29 manufacturing plants in 10 countries. Out of 20 manufacturing plants in the MENA region, there are five plants in the Middle East (four in Jordan and one in the Kingdom of Saudi Arabia - KSA) which are US Food and Drug Administration (FDA) inspected. Hikma’s business lines include branded, injectable and generic pharmaceuticals. IFC provided a financing package (the “Financing Package”) to Hikma Finance USA LLC (the “Borrower”), a wholly owned subsidiary of Hikma. Proceeds of the IFC Loan (as defined below) and the Bond (as defined below) which, for the avoidance of doubt, is limited to IFC’s subscription of US$50 million in the Bond, will be used to support the Company’s general corporate purposes including acquisitions, capital expenditure, working capital needs, and any investment in research and development in the Middle East region, as well as debt refinancing of the Group (the “Project”). The Financing Package will primarily support Hikma’s existing operations in the Middle East region, including but not limited to facilities in Jordan (five manufacturing plants and two R&D centers) and KSA (three manufacturing plants and one R&D center).The Financing Package entails (i) a 6-year senior unsecured A loan of US$250 million, to the Borrower – processed under IFC project Hikma Loan 2025 (#51629) (the “IFC Loan”); and (ii) a subscription of US$50 million in Hikma Finance’s US$500 million bond (the “Bond”), in which IFC played an anchoring role – processed under IFC project Hikma Bond (#51148).Hikma is a long-standing IFC client since 1987 whereby support was primarily provided to the Company’s investments in the MENA region including financing of acquisitions in Algeria, Tunisia, Morocco and Egypt. IFC has two active investments with the Group, Hikma Expansion (#37324) and RSE Hikma (#44224), and its environmental and social (E&S) performance is satisfactory. |
Original sub-sector | Obfuscated |
Original Currency | USD |
Original budget | 000000000000000 |
Procurement method | Obfuscated Data |
Budget | 000000000000000 |
Location
Region | Obfuscated |
Country | Obfuscated |
State | Obfuscated Data |
County | Obfuscated |
Location | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Source
Source reliability | High |
Data quality score | 100% |
Source | Obfuscated Data |
URL | obfuscated_data,obfuscateddata.com |
More Details
Project Type | Obfuscated Data |
Article Published Date | Obfuscated Data |
